Prot #18157/NU COH19H01: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Project: Research project

StatusActive
Effective start/end date8/12/198/12/22

Funding

  • City of Hope National Medical Center (Prot #18157/NU COH19H01)
  • Bristol-Myers Squibb Company (Prot #18157/NU COH19H01)